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Hematopoietic stem cells (HSCs) are self-renewing
multipotent stem cells that generate mature blood
lineages throughout life. They, together with he-
matopoietic progenitor cells (collectively known
as HSPCs), emerge from hemogenic endothelium
in the floor of the embryonic dorsal aorta by
an endothelial-to-hematopoietic transition (EHT).
Here we demonstrate that transforming growth fac-
tor b (TGFb) is required for HSPC specification and
that it regulates the expression of the Notch ligand
Jagged1a in endothelial cells prior to EHT, in a
striking parallel with the epithelial-to-mesenchy-
mal transition (EMT). The requirement for TGFb
is two fold and sequential: autocrine via Tgfb1a
and Tgfb1b produced in the endothelial cells them-
selves, followed by a paracrine input of Tgfb3 from
the notochord, suggesting that the former programs
the hemogenic endothelium and the latter drives
EHT. Our findings have important implications for
the generation of HSPCs from pluripotent cells
in vitro.
INTRODUCTION
Hematopoietic stem cells (HSCs) are specified during embryonic
development from a subset of arterial endothelial cells located in
the floor of the dorsal aorta (DA). HSCs emerge by a process
termed the endothelial-to-hematopoietic transition (EHT) (Ber-
trand et al., 2010; Boisset et al., 2010; Kissa and Herbomel,
2010). In zebrafish, the hematopoietic stem and progenitor cells
(HSPCs) generated by EHT migrate to the caudal hematopoietic
tissue (CHT), where they proliferate and undergo differentiation
into erythroid andmyeloid lineages (Kissa et al., 2008;Murayama
et al., 2006). Some will exit the CHT and migrate to the thymus to
give rise to T cells, and others move to the kidney, the adult site
of hematopoiesis in the zebrafish, equivalent to the bonemarrow
in mammals (Ciau-Uitz et al., 2014).358 Developmental Cell 38, 358–370, August 22, 2016 ª 2016 The A
This is an open access article under the CC BY license (http://creativeThe transcription factor Runx1 is required for EHT in mice
and zebrafish (Chen et al., 2009; Kissa and Herbomel, 2010).
Its expression in the floor of the DA is initiated by 23 hpf in ze-
brafish (Wilkinson et al., 2009) and marks a cell population
committed to the hemogenic fate, the hemogenic endothelium
(HE). Several signaling pathways including Hedgehog, VEGF,
Notch and BMP are required sequentially to regulate program-
ming of the arterial endothelium and HSPC emergence (Burns
et al., 2005; Gering and Patient, 2005; Kim et al., 2014; Wilkin-
son et al., 2009). The Notch receptor Notch1 is the main driver
of HSPC emergence from HE, likely downstream of its ligand
Jagged1 (Gama-Norton et al., 2015; Hadland et al., 2015;
Jang et al., 2015) and is thought to drive runx1 expression
via Gata2 (Robert-Moreno et al., 2005). Jagged1 is dispens-
able for arterial programming but required in the endothelium
for the specification of HSPCs (Espin-Palazon et al., 2014;
Gama-Norton et al., 2015; Robert-Moreno et al., 2008).
In humans, defective transforming growth factor b (TGFb)
signaling is associated with proliferative disorders of HSPCs
such as acute myeloid leukemia and T cell acute lymphoblastic
leukemia (Kim and Letterio, 2003). More recently, it has been
shown that paracrine TGFb signaling in the bone marrow niche
maintains quiescence of the resident HSC pool (Zhao et al.,
2014) and may also direct differentiation of lineage-biased HSC
subtypes (Challen et al., 2010), positioning TGFb as a critical
regulator of proliferation and differentiation of adult HSCs.
Whether TGFb plays a role in the formation of HSCs is however
not known.Mutants for the ligand TGFb1 or its receptor TGFbR2,
including endothelial-specific conditional knockout mice, die
between E9.5 and E10.5 due to defective recruitment of mural
cells to the yolk sac vasculature and the subsequent loss of
vessel integrity (Carvalho et al., 2004; Dickson et al., 1995; Osh-
ima et al., 1996). This is before the emergence of HSPCs in the
embryo proper (de Bruijn et al., 2002), effectively precluding the
analysis of the role of TGFb signaling in HSPC specification in
mice. Zebrafish, however, develop externally and do not depend
on extraembryonic tissues for survival. In addition, recruitment of
mural cells to the endothelium does not happen until 72 hpf (San-
toro et al., 2009), 2 days after the HSPCs are specified in the DA.
Thus, we can address the role of TGFb in HSPC emergence in
zebrafish without the inherent limitations of the mouse models.uthor(s). Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
The TGFb superfamily comprises BMPs, Activins, Nodals, and
TGFbs. There are three TGFb ligands in the mouse: TGFb1,
TGFb2, and TGFb3 (Goumans and Mummery, 2000), and they
all signal through a single type II serine-threonine kinase receptor
(TGFbR2) that recruits the type I receptors Activin-like kinase 1
(Alk1) or Alk5 (Shi and Massague, 2003). Alk1 expression is
essentially restricted to endothelial cells (ECs) (Oh et al., 2000),
whereas Alk5 is more broadly expressed (Goumans et al.,
2002) but also present in ECs. Activated Alk1 phosphorylates
Smad1, Smad5, and Smad9, whereas activated Alk5 phosphor-
ylates Smad2 and Smad3 (Shi and Massague, 2003). Activated
Smads migrate to the nucleus together with the co-Smad
Smad4 and regulate transcription together with co-activators
or co-repressors (Shi and Massague, 2003). In addition, TGFb
can signal through the non-canonical Erk, JNK, and p38 MAPK
kinase pathways to instigate transcriptional responses (Derynck
and Zhang, 2003). Thus, to circumvent the complexity of the
intracellular signaling elicited by TGFb, we focused our attention
on TgfbR2, the type II receptor for TGFb. Abrogation of TGFbR2
activity revealed that TGFb signaling plays a key role in the for-
mation of HSPCs. TGFb is required for the correct programming
of the HE downstream of Vegf and independently of arterial pro-
gramming. We demonstrate that Jag1a is a target of TGFb
signaling, and jag1a overexpression in endothelium rescues
the loss of HSPCs in tgfbR2-depleted embryos. Finally, we iden-
tified two independent sources of ligand: TGFb1a and TGFb1b in
the endothelium and TGFb3 in the nearby notochord. Both inputs
contribute to the regulation of jag1a in endothelium through the
TgfbR2 receptor and thus enable Notch signaling to program
the HE prior to specification of HSPCs.
RESULTS
TGFb Signaling Components Are Expressed in or around
the Embryonic Site of HSC Emergence
To investigate whether TGFb signaling could play a role in HSPC
specification in zebrafish, we first carried out expression anal-
ysis. tgfbR2 is expressed in the head vasculature and in the so-
mites at 15 hpf and in the DA and the somites from at least 18 hpf
up to 24 hpf (Figures 1A and S1A), prior to the onset of runx1
expression in the HE (Wilkinson et al., 2009). At 30 hpf, tgfbR2
becomes essentially endothelial, with higher expression in the
posterior cardinal vein (PCV) and in the caudal plexus (Figure 1A).
TGFb ligands are also expressed in the region at the onset of HE
formation: tgfb1a and tgfb1b are expressed in the endothelium,
including the DA at 15 hpf, 24 hpf, and 27 hpf (Figures 1B, 1C,
S1B, and S1C). At 27 hpf, tgfb1a expression is downregulated
in the DA and PCV, whereas tgfb1b is still clearly present (Figures
1B and 1C). Tgfb2 is expressed in the notochord at 12 hpf, 20
hpf, and 24 hpf (Figures 1D and S1D), and tgfb3 is expressed
in the notochord and in the 3–4 anterior-most somites from 12
hpf to 20 hpf and also in ECs in the head (Figures 1E and S1E).
From 20 hpf onward, tgfb3 was found in the dorsal tip of the
somites, the floorplate, and in the notochord (Figure 1E).
TGFb Signaling through TgfbR2 Is Required for the
Specification of HSPCs
To investigate whether TGFb signaling is required for the speci-
fication of HSPCs, we designed an antisense morpholino oligo-nucleotide (MO) targeting the start site of tgfbR2 translation
(tgfbR2MO1; Figure S2A) and verified that it decreased TgfbR2
protein levels at 26 hpf (Figure S2B). TgfbR2morphants showed
a severe decrease in expression of runx1, gfi1aa, and gata2b,
two other HE markers (Butko et al., 2015; Cooney et al., 2013),
at 26–28 hpf (Figures 2A–2F), suggesting that HSPC emergence
is impaired. Specification of the arterial program in the endo-
thelium of the DA by Notch signaling is required for HSPC emer-
gence (Burns et al., 2005; Gering and Patient, 2005). Therefore,
we asked if either the endothelial or the arterial programs are
affected by loss of TGFb signaling. We found that the pan-endo-
thelial kdrl and the arterial markers notch3, hey2, and efnb2a
were unaffected in tgfbR2 morphants (Figures 2G–2N).
HSPCs emerging from the DA express kdrl and low levels
of itga2b (also known as CD41) in itga2b:GFP;Kdrl:HsRas-
mCherry transgenic embryos (Kissa et al., 2008). To quantitate
the loss of HSPCs in tgfbR2 morphants, we counted the
number of Kdrl-mCherry+;itga2b-GFPlow HSPCs in the DA of
live itga2b:GFP;Kdrl:HsRas-mCherry transgenic embryos by
confocal microscopy at 48 hpf (Figures 2O–2Q). In tgfbR2 mor-
phants, the number of Kdrl-mCherry+;itga2b-GFPlow HSPCs
was reduced more than 2-fold compared with uninjected em-
bryos (Figure 2Q). The loss of itga2b-GFPlow cells in tgfbR2
morphants was still evident at 5 dpf (Figures 2R and 2S) and,
consistent with this, we found that the expression of the HSPC
markers runx1, cmyb, and ikzf1 was severely downregulated in
tgfbR2morphants at 48 hpf (Figure S2D). cmyb, ikzf1, and l-plas-
tin (pan-leukocyte marker) were severely reduced in the CHT
and in the thymus at 4 dpf (Figures S2E and S2F). Expression
of the early T cell marker rag1 in the thymus (Figures 2T and
2U) and the erythroid marker hbbe1 in the CHT (Figures 2V
and 2W) were also severely reduced. Taken together, these
experiments indicate that TGFb signaling is required for the
specification of HSPCs.
We designed a second MO, tgfbR2MO2 that blocks splicing of
exon 4 of tgfbR2 (Figure S2A), and confirmed the results ob-
tained with tgfbR2MO1 (Figure S2G). Neither the pan-endothelial
marker fli1 nor the arterial markers dll4 and dlC were affected in
tgfbR2MO1 and tgfbR2MO2 morphants (Figure S2G). To examine
whether TGFb signaling is also required for primitive hematopoi-
esis, we performed in situ hybridization for scl, gata1, and pu.1 at
20 hpf (Figure S2H) and gata1 and pu.1 at 24 hpf (Figure S2I).
TgfbR2 morphants showed no significant change in expression
of these markers, suggesting that specification of primitive he-
matopoietic cells does not require TGFb signaling through
TgfbR2. However, maturation of primitive erythrocytes was
slightly impaired, as suggested by a small decrease in o-dianisi-
dine staining in tgfbR2 morphants at 36 hpf (Figure S2J).
Taken together, our data show that TGFb signaling through
TgfbR2 is required for the specification of HSPCs independently
of arterial programming.
TGFb1 in the Arterial Endothelium and TGFb3 from the
Notochord Are Required for HSPC Emergence
Tgfb1/ and TgfbR2/ mouse mutants share a similar vascu-
logenic phenotype in the yolk sac (Dickson et al., 1995; Oshima
et al., 1996); thus we reasoned that TGFb1 was the like-
liest ligand for TgfbR2 in HSPC emergence. To test this hypoth-
esis, we knocked down tgfb1a or tgfb1b with at least twoDevelopmental Cell 38, 358–370, August 22, 2016 359
Figure 1. TGFb Signaling Components Are Expressed in and around the Embryonic Dorsal Aorta
(A) Expression of tgfbR2 at (i) 18 hpf and (ii–iv) 24 hpf, including the somites, dorsal aorta (DA), and gut. (v–vi) At 30 hpf, expression was confined to the DA,
notochord, posterior cardinal vein (PCV), and some of the surrounding mesenchyme.
(B) Expression of tgfb1a in the DA at (i) 20 hpf and (ii, iii) in the DA, PCV, and intersomitic vessels (ISVs) at 24 hpf. At 27 hpf, there was very little expression of tgfb1a
remaining in the DA.
(C) tgfb1b is also expressed in the DA (i) at 20 hpf and in the DA and PCV at (ii) 24 hpf and (iii) 27 hpf. (iv, v) Transversal sections show tgfb1b expression at 24 hpf in
the DA and PCV. (vi) Tgfb1b was still apparent in the DA and PCV by 27 hpf.
(D) Expression of tgfb2 at (i) 20 hpf and (ii) 24 hpf. Notochord-specific expression was found throughout all the stages analyzed.
(E) Expression of tgfb3 at (i) 20 hpf, (ii) 24 hpf, and (iii) 27 hpf. (iv, v) Transversal section at 24 hpf, showing expression in the dorsal tip of the somites, notochord,
and floorplate. (vi) Expression in the notochord and floorplate was maintained at 27 hpf. Note that tgfb3 is absent from the DA.
g, gut; dt, dorsal tip of the somite; fp, floorplate; isv, intersomitic vessel; n, notochord; nt, neural tube; som, somite. See also Figure S1.splice-blocking morpholinos for each (Figures S3A–S3F) and
found partial loss of runx1 and cmyb in the DA without affecting
expression of the arterial marker dll4 (Figure S3F and data not
shown). Co-injection of half the amounts of tgfb1aMO2 and
tgfb1bMO2 (7.5 + 10 ng, respectively, referred to as tgfb1MO2)
induced a severe loss of runx1 and cmyb expression in a higher
proportion of embryos at 28 hpf when compared with single
tgfb1a or tgfb1b morphants (Figures 3A, S3E, and S3F; and re-
sults not shown), suggesting that, in single morphants, the360 Developmental Cell 38, 358–370, August 22, 2016TGFb1 ligands can partially compensate for the other’s
absence and that both are required for HSPC emergence.
Knocking down tgfb2 with a splice-blocking morpholino
(tgfb2MO3; Figure S3G) had very little effect on runx1 expression
(Figure 3A), whereas over half (28/50) of the tgfb3 morphants
(tgfb3MO2, Figure S3H) showed a severe decrease in runx1 in
the DA at 28 hpf (Figure 3A). Expression of kdrl in the en-
dothelium and dll4 and dlC in the arterial endothelium was un-
affected in tgfb1MO2, tgfb2MO3, or tgfb3MO2 morphant embryos
Figure 2. TGFb Signaling Is Required for Specification of HSCs
Expression of runx1 in (A) wild-type (wt) and (B) tgfbr2morphants at 26 hpf. Expression of gfi1aa in (C) wild-type or (D) tgfbr2morphants at 26 hpf. Expression of
gata2b in (E) wild-type or (F) tgfbr2 morphants at 26 hpf.
Expression of the vascular marker kdrl (G, H) and the arterial markers notch3 (I, J), hey2 (K, L), and efnB2A (M, N) is unaffected in tgfbR2 morphants. Maximum
projections of itga2b:GFP; Kdrl:HRas-mCherry transgenic embryos at 48 hpf in (O) uninjected and (P) tgfbr2MO1-injected embryos. Region shown includes part
of the DA and white arrowheads denote itga2b:GFP+(green), kdrl:HRas-mCherry+ (magenta) HSPCs.
(Q) HSPC counts in the entire trunk region of uninjected and tgfbR2morphant itga2b:GFP; Kdrl:HRas-mCherry transgenic embryos at 48 hpf (p value is indicated
on the graph, n = 12 (wild-type) and n = 11 (tgfbR2MO1).
itga2b-GFP+ cells are present in the CHT of itga2b:GFP embryos (R, yellow arrowheads) and greatly reduced in the CHT of tgfbR2 morphants at 5 dpf (S).
Expression of rag1 in the thymus (red arrowheads) at 4 dpf in (T) wild-type and (U) tgfbR2morphants. Expression of hbbe1 in the CHT at 4 dpf in (V) wild-type and
(W) tgfbR2 morphants.
The numbers of embryos are shown in each panel as the number of embryos with phenotype/total number analyzed. See also Figure S2.(Figures 3B–3D), consistent with TGFb signaling being required
for HSPC specification but not for arterial programming. To
quantitate the effect, we counted the number of Kdrl-
mCherry+;itga2b-GFPlow HSPCs at 48 hpf (Figures 3E–3H).
Both tgfb1MO2 and tgfb3MO2 morphants showed severely
reduced numbers of HSPCs when compared with uninjected
embryos. tgfb3MO2 morphants had fewer HSPCs than tgfb1MO2
morphants at 48 hpf (Figure 3H), which correlated with a stron-
ger decrease in rag1 expression in the thymus of tgfb3MO2 mor-
phants at 4 dpf (Figures 3I–3K). Further analysis revealed that
expression of the arterial marker efnB2a was unaffected,
whereas that of the HE marker gata2b was reduced in tgfb1MO2
and in half of the tgfb3MO2 embryos (Figures 3L and 3M). Nextwe investigated whether the milder phenotype in tgfb3 mor-
phants was due to upregulation of Tgfb1. We found that
tgfb3 was essentially absent in tgfb3MO2 morphants but tgfb1a
or tgfb1b expression was unaffected (Figure S3I). Conversely,
tgfb1 morphants showed increased tgfb3 expression in the
notochord (Figure S3I). Knocking down tgfb1 in tgfb3 mor-
phants increased the percentage of embryos with reduced
runx1 expression from 50% to 85% (Figures S3J and S3K),
suggesting that Tgfb1 and Tgfb3 have an additive effect on
HSPC specification. Taken together, we conclude that
Tgfb1a/1b produced by the ECs of the DA are required for
HSPC formation by programming the HE downstream or in par-
allel to arterial programming. In addition, there is a significantDevelopmental Cell 38, 358–370, August 22, 2016 361
paracrine contribution by Tgfb3, which becomes a more impor-
tant regulator of HSPC generation between 28 and 48 hpf.
Vegf Signaling Regulates Expression of the tgfb1a and
tgfb1b Ligands in the Dorsal Aorta
The sequential activity of VegfA and Notch is required for pro-
gramming the DA endothelium to become arterial and give rise
to HSPCs (Burns et al., 2005; Gering and Patient, 2005; Leung
et al., 2013). Because our data suggest that the requirement
for TGFb lies downstream or parallel to arterial programming
by Notch signaling (Figures 1, 2, and 3), we asked whether
Vegf or Notch signaling might act as upstream transcriptional
regulators of TGFb ligands. To address this, we treated wild-
type embryos after gastrulation with selective inhibitors for
Vegf (DMH4, 20 mM) and Notch signaling (DAPM, 100 mM) (Hao
et al., 2010; Walsh et al., 2002) and examined the expression
of tgfb1a, tgfb1b, tgfb3, and tgfbR2 (Figure 4). DMH4-treated
embryos failed to form intersomitic vessels as expected (Bahary
et al., 2007) and showed diminished kdrl expression in the trunk
vasculature when compared with DMSO-treated controls (Fig-
ure 4A). The DAPM treatment had no effect on kdrl expression
(Figure 4A). Blocking either Vegf or Notch signaling led to loss
of runx1 from the floor of the DA by 28 hpf, as described (Burns
et al., 2005; Gering and Patient, 2005; Lam et al., 2010) (Fig-
ure 4B). To ask whether the loss of kdrl expression upon inhibi-
tion by DMH4 was due to transcriptional regulation by Vegf,
we repeated the experiment in Tg(Fli1:EGFP) embryos. We
confirmed that intersomitic vessels were absent but trunk ECs
were still present in DMH4-treated embryos (Figure 4C). Analysis
by qPCR showed that kdrl was decreased in DMH4-treated Fli-
EGFP+ ECs (Figure 4D). Strikingly, inhibition by DMH4 led to
decreased tgfb1a and tgfb1b in the endothelium, whereas
DAPM treatment had no obvious effect (Figures 4D and 4E).
Tgfb3 and tgfbR2 were unaffected by either treatment, suggest-
ing that only tgfb1a and tgfb1b are Vegf-dependent. These re-
sults were confirmed by morpholino knockdown of the Vegf re-
ceptors, kdr and kdrl (Figure S4A). Next we asked whether
Wnt16 and BMP4, which are required for HSPC formation inde-
pendently of Vegf or Notch signaling in the endothelium (Clem-
ents et al., 2011; Wilkinson et al., 2009), could be upstream reg-
ulators of TGFb. Knocking down either Wnt16 or BMP4 had no
effect on TGFb ligand or receptor expression (Figure S4B).
Thus, we conclude that Vegf signaling is an upstream regulator
of TGFb signaling by positively regulating expression of tgfb1a
and tgfb1b in ECs (Figure 4F) before HSPC specification.
The Notch Ligand Jag1a Is a Downstream Target of
TGFb Signaling in Endothelial Cells
Formation of HSPCs requires many cell extrinsic and intrinsic
factors (ligands, receptors, transcription factors, and chromatin
modifiers). Thus, to investigate whether any of the known
pathways required to specify HSPCs are regulated by TGFb
signaling, we used the NanoString gene quantitation system
(Geiss et al., 2008). We designed a custom panel of 132
NanoString probes that included Vegf, Notch, BMP, Wnt, Hh,
and TGFb signaling pathway components or targets. The probe
set also contained known blood and endothelial genes, cell-cy-
cle and apoptosis genes, mediators of EMT, and six house-
keeping genes for data normalization. To assess expression362 Developmental Cell 38, 358–370, August 22, 2016changes in the somites as well as in the endothelium, we
dissected the trunks of wild-type and tgfbR2 morphant em-
bryos at 26 hpf and isolated total RNA to hybridize against
the NanoString probe set (Figure 5A). Only nine of the genes
probed showed statistically significant differences in expres-
sion (p < 0.05 and an absolute logFC >0.5) between wild-type
and tgfbR2 morphants, importantly including decreased runx1
expression in the morphants (Figure 5B and Table S1). Applying
a more stringent filtering (false discovery rate <0.1) yielded a
smaller high-confidence subset of differentially expressed
genes in tgfbR2 morphants (Figure 5C). Five of six genes in
this subset were upregulated and three of those, p53, cdkn1a,
bax, are associated with apoptosis and cell-cycle arrest
(Menendez et al., 2009). A fourth gene, rspo1, is an agonist of
Wnt signaling that is required for sprouting angiogenesis
(Gore et al., 2011) and is expressed at very low levels in wild-
type embryos (Table S1). Taz, a Wnt signaling mediator (Azzolin
et al., 2012), was also upregulated in our assay, suggesting a
link between TGFb and Wnt signaling. However, when we
sorted kdrl:GFP+ ECs versus kdrl:GFP cells from control
embryos and tgfbR2 morphants (Figure 5D), we found no sig-
nificant difference in rspo1 expression by qPCR in either popu-
lation (Figures 5E and 5F). Analysis of p53, cdkn1a, and bax
expression by qPCR showed that only p53 and cdkn1a were
significantly upregulated in ECs (Figure 5E), whereas all three
were upregulated in kdrl:GFP cells (Figure 5F). These results
suggested that tgfbR2 morphants might show increased
apoptosis. Thus we performed a TUNEL assay for apoptotic
cells in Kdrl:GFP transgenic embryos and found a marked in-
crease in TUNEL+ (apoptotic) cells in the trunk and tail regions
of 30 hpf tgfbR2 morphants compared with control embryos
(Figures 5G and 5H). We found increased apoptosis in ECs in
the tail vascular plexus (Figure 5H0, white arrows) but not in
the trunk vasculature (Figure 5H) where HSPCs arise. Thus, if
p53 and its targets cdkn1a and bax play a role in HSC specifi-
cation downstream of TGFb, it appears to be independent of
their pro-apoptotic activity. The increase in p53 could have
been non-specific due to the injection of MOs, as previously re-
ported (Robu et al., 2007). However, knocking down runx1 also
led to an increase in p53, cdkn1a, and baxa (Figure S5K). This
raises the possibility that the increase in pro-apoptotic gene
expression in tgfbR2 morphants could be indirect, acting
downstream of Runx1.
Strikingly, jag1a was the only gene besides runx1 that was
significantly downregulated in tgfbR2 morphants (Figures 5B
and 5C). Neither its paralog jag1b nor any of the other Notch li-
gands or receptors in the probe set were significantly affected
by loss of TGFb signaling (Figure S5A). To confirm that jag1a
was downregulated in the absence of TGFb signaling, we in-
jected tgfbR2MO1 into Kdrl:GFP embryos, sorted GFP+ ECs
and GFP cells, and assayed jag1a expression by qPCR. jag1a
was downregulated in both populations (Figures 5I and 5J).
dll4 and gata2a expression was unaltered in ECs from tgfbR2
morphants (Figure S5L), confirming the NanoString results. To
determine which TGFb ligand regulates jag1a, we assayed its
expression in tgfb1MO2 and tgfb3MO2 morphants compared
with wild-type embryos at 26 hpf. Jag1a was downregulated in
both tgfb1MO2 and tgfb3MO2morphants (Figure S5M). Moreover,
tgfb1MO2 and tgfb3MO2 morphants showed increased p53 and
Figure 3. TGFb1 and TGFb3 Are Required for Specification of HSCs
(A) Expression of runx1 in wild-type, tgfb1, tgfb2, and tgfb3 morphants.
(B) Expression of kdrl in wild-type, tgfb1, tgfb2, and tgfb3 morphants.
(legend continued on next page)
Developmental Cell 38, 358–370, August 22, 2016 363
Figure 4. Vegf Signaling Is Required for tgfb1a and tgfb1b Expression in the Dorsal Aorta
(A and B) Wild-type embryos were treated from 10 hpf with DMSO (control), Vegf inhibitor DMH4 (20 mM), and Notch inhibitor DAPM (100 mM) and collected at
22 hpf or 28 hpf. Embryos were collected and analyzed for (A) kdrl expression at 22 hpf and (B) runx1 expression at 28 hpf.
(C) Tg(Fli1:EGFP) embryos were treated from 10 to 26 hpf with DMSO or DMH4 (20 mM). DMH4-treated embryos showed a severe loss of intersomitic vessels but
ECs are still present in the trunk, and circulation was detected in a majority of embryos at 48 hpf (data not shown).
(D) Expression of kdrl, tgfb1a, tgfb1b by qPCR in 26 hpf sorted Fli1:EGFP+ ECs. All three genes were downregulated after DMH4 treatment. Results are shown as
averages ± SD of 4–5 biological replicates.
(E) Wild-type embryos were treated from 10 hpf with DMSO (control), Vegf inhibitor DMH4 (20 mM), and Notch inhibitor DAPM (100 mM) and collected at 22 hpf for
analysis of tgfb1a, tgfb1b, tgfb3, and tgfbR2 by in situ hybridization at 22 hpf.
(F) Schematic representation of the experimental results.
Black arrows indicate the location of the DA; yellow arrowheads indicate the location of runx1 expression in the floor of the DA. The numbers of embryos are
shown in each panel as the number of embryos with phenotype/total number analyzed. Arterial EC, arterial endothelial cell.
See also Figure S4.no effect on gata2a or dll4 expression (Figure S5N). Thus, our
data indicate that jag1a is a TGFb target in the endothelium at
the onset of HSPC specification and suggest that both TGFb1
and TGFb3 contribute to the expression of jag1a.(C) Expression of dll4 in wild-type, tgfb1, tgfb2, and tgfb3 morphants.
(D) Expression of dlC in wild-type, tgfb1, tgfb2, and tgfb3 morphants. All sample
(E–G) Maximum projections of itga2b:GFP; Kdrl:HRas-mCherry transgenic embry
images show part of the trunk DA and white arrowheads denote itga2b:GFP+ (gr
(H) HSPCs counts in the entire trunk region of uninjected, tgfb1, and tgfb3 morph
indicated on the graph, n = 10 for each of the conditions).
(I–K) Expression of rag1 in the thymus at 4 dpf (red arrowheads) in (I) wild-type, (
(L) Expression of efnB2a in wild-type, tgfb1, and tgfb3 morphants.
(M) Expression of gata2b in wild-type, tgfb1, and tgfb3morphants. The numbers o
total number analyzed.
See also Figure S3.
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the HE
To determine if Jag1a is required for arterial programming or
HSPC specification in zebrafish, we knocked down jag1as were analyzed at 28 hpf.
os in (E) uninjected, (F) tgfb1morphants, and (G) tgfb3morphants at 48 hpf. The
een), kdrl:HRas-mCherry+ (magenta) HSPCs.
ant itga2b:GFP; Kdrl:HRas-mCherry transgenic embryos at 48 hpf (p value is
J) tgfb1 morphants, and (K) tgfb3 morphants.
f embryos are shown in each panel as the number of embryos with phenotype/
Figure 5. Multiplex Analysis of Gene Expression Shows that jag1a Is a Downstream Target of TGFb Signaling
(A) Schematic representation of the trunk dissection experiment for isolation of mRNA for hybridization with the NanoString Probe CodeSet. Six groups of
independent wild-type (wt1–6) and tgfbR2MO1-injected embryos (mo1-6) were used in this analysis.
(B) Volcano plot depicting differential gene expression between wild-type and tgfbR2morphants in log2-fold change with a significance level of p < 0.05. Vertical
broken lines limit the absolute logFC larger than 0.5-fold change range, whereas the horizontal broken line represents the false discovery rate (FDR) threshold set
at FDR < 0.1. The genes where FDR < 0.1 are shown as orange dots. The size of the dots is proportional to mRNA expression levels.
(legend continued on next page)
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Figure 6. Jag1a Is Required Downstream of TGFb Signaling for HSC Specification
(A) Expression of arterial markers in jag1aMO is unaffected when compared to wild-type embryos.
(B) Expression of runx1, cmyb, and gfi1aa in wild-type and jag1amorphants (MO) at 28 hpf. All the markers analyzed are reduced or absent in jag1amorphants.
Red arrowheads indicate the remaining gene expression in the floor of the DA of jag1a morphants.
(C) HSPCs (yellow arrowheads) are severely reduced in the CHT of itga2b:GFP;Kdrl:HsRas-mCherry transgenic embryos at 48 hpf injected with the jag1aMO.
Itga2b:GFP+ cells, magenta; Kdrl-HsRas:mCherry+ cells, green.
(D) Overexpression of jag1a with a Kdrl:jag1-V5 construct partially rescues the loss of runx1 and cmyb in the floor of the DA. 15 pg of the construct was used for
this experiment. The numbers of embryos are shown in each panel as the number of embryos with phenotype/total number analyzed.
(E) Quantitation of the rescue effect observed in (D).
See also Figure S6.with a specific morpholino (Yamamoto et al., 2010) and found
no obvious defects in arterial programming compared with
wild-type embryos (Figure 6A). However, expression of the
HSPC markers runx1, cmyb, and gfi1aa was severely downre-
gulated in jag1a morphants at 28 hpf (Figure 6B). Furthermore,
itga2b:GFP+ HSPCs were nearly absent in the CHT of jag1a
morphants by 48 hpf (Figure 6C) suggesting that the HE was
mis-programmed and failed to give rise to HSPCs in the
absence of Jag1a. A recent study showed that jag1a is regu-(C) Hierarchical clustering of genes expressed with FDR < 0.1 in each of the six b
Results are normalized and presented as Z scores from 2 (downregulated) to 2
(D) Schematic representation of the sorting of kdrl:GFP+ cells in wild-type and tgfb
validate the NanoString results by qPCR.
(E and F) qPCR of p53, cdkn1a, rspo1, and bax in (E) kdrl:GFP+ cells and (F) kdrl:G
from the analysis as its fold induction <2.
(G and G0) TUNEL-stained apoptotic cells in uninjected (control) kdrl:GFP embry
(H and H0) Apoptotic cells in tgfbR2MO1-injected kdrl:GFP embryos at 30
non-endothelial cells.
(I and J) qPCR for jag1a in (I) kdrl:GFP cells and (J) in kdrl:GFP+ cells at 28 hpf.
See also Figure S5 and Table S1.
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zon et al., 2014). Expression of tnfR2 in ECs was unaffected in
tgfbR2 morphants (Figure S6), suggesting that TGFb does not
regulate jag1a indirectly via regulation of tnfr2. To determine if
Jag1a is the main target of TGFb signaling in HSPC specifica-
tion, we restored Jag1a expression specifically in the endothe-
lium of tgfbr2MO1 morphants using a Kdrl:jag1a construct.
Wild-type embryos overexpressing jag1a in ECs showed little
effect on expression of runx1 or cmyb at 28 hpf (Figures 6Diological replicates analyzed (wild-type, wt1 to wt6; tgfbR2MO1, mo1 to mo6).
(upregulated).
R2morphants (MO) by fluorescence-activated cell sorting to isolatemRNA and
FP cells of wild-type and tgfbR2morphants (MO) at 28 hpf. Taz was omitted
os at 30 hpf.
hpf. White arrows, apoptotic endothelial cells; outline arrows, apoptotic
and 6E). However, forced expression of jag1a in the endothe-
lium of tgfbR2 morphants rescued the loss of runx1 and
cmyb expression (Figures 6D and 6E), confirming that the he-
matopoietic defects in tgfbR2 morphants are mainly due to
loss of jag1a. We conclude that autocrine TGFb1 and paracrine
TGFb3 signal to the endothelium through TgfbR2, inducing
jag1a expression, which in turn induces HE programming and
HSPC emergence.
DISCUSSION
TGFb Is a Regulator of HSPCSpecification in the Embryo
We have demonstrated a critical role for TGFb signaling in the
specification of HSPCs. Our data show that knockdown of the
type II receptor for TGFb leads to the loss of HSPCs and their
differentiated progeny. Cell-autonomous Notch signaling is
required for the programming of arterial identity in the endo-
thelium (Quillien et al., 2014) and failure to acquire this identity,
through the absence of Notch signaling or Hey2, leads to loss
of HSPCs (Gering and Patient, 2010; Kim et al., 2014; Rowlin-
son and Gering, 2010). However, recent publications suggest
that arterial identity is not an absolute requirement for HE
specification and HSPC emergence (Ditadi et al., 2015; Jang
et al., 2015). Here we show that neither Hey2 nor the Notch
pathway components that program the artery are affected
by the absence of TGFb signaling, whereas the HE markers
gata2b, runx1, and gfi1aa are strongly downregulated. Thus,
we propose that TGFb functions independently of arterial
development to program the arterial ECs to become
hemogenic.
Parallel Activation of Notch and TGFb Signaling by Vegf
Programs the HE
Vegf and TGFb are important regulators of vasculogenesis and
angiogenesis in both embryonic development and cancer pro-
gression (Holderfield and Hughes, 2008), and crosstalk between
themhas been demonstrated,mainly through regulation of vegfA
by TGFb (Massague and Gomis, 2006). Here we show the oppo-
site: expression of tgfb1a and tgfb1b ligands is dependent on
VegfA signaling through its receptors Kdr andKdrl. Vegf also reg-
ulates the expression of hey2, notch3, and notch1b, which are
required for arterial programming (Gering and Patient, 2005;
Lawson et al., 2002; Rowlinson and Gering, 2010). Thus, we pro-
pose that HSPC emergence requires parallel activation of both
pathways by Vegf, where Notch signaling provides the arterial
identity and TGFb programs the endothelium to become
hemogenic.
TGFb and Notch Crosstalk in EHT: Similarities to
Epithelial-to-Mesenchymal Transition
Because tgfbR2 is expressed in the DA prior to HSC specifica-
tion (Figures S1 and S2), we propose that TGFb ligands act
directly on ECs, resulting in jag1a activation. Jag1a then acti-
vates the Notch receptor, presumably Notch1a (Espin-Palazon
et al., 2014), and the signal-receiving cell becomes hemogenic
by expressing specific markers such as gata2b, runx1, and
gfi1aa. Loss of TGFb signaling would therefore prevent HE
from being specified by the Jag1a/Notch1a interaction. Thus,
the concerted activities of TGFb and Notch signaling explainhow only some of the ECs in the floor of the aorta are pro-
grammed to become hemogenic. Interestingly, jag1 expression
is also induced by TGFb prior to EMT and is required for epithelial
cells to progress to the mesenchymal fate in oncogenic transfor-
mation (Zavadil et al., 2004). In development, the cardiac cushion
arises by an endothelial-to-mesenchymal transition (EndoMT)
and this is also dependent on crosstalk between TGFb and
Notch signaling (Lamouille et al., 2014). Thus, this crosstalk
between TGFb and Notch signaling is a shared feature between
EMT, EndoMT, and EHT. The similarity between these processes
may guide future studies on the molecular and cellular basis
of EHT.
TGFb1a, TGFb1b, and TGFb3 Are Required Sequentially
to Generate HSPCs
Genetic studies in mice suggested that paracrine TGFb is pri-
marily required to recruit smooth muscle cells to the endothe-
lium (Pardali et al., 2010). In addition, autocrine signaling in
ECs is important to regulate proliferation and migration (Par-
dali et al., 2010). Thus, TGFb acts both in an autocrine and
paracrine fashion in vivo. Similarly, here we describe two inde-
pendent sources of TGFb ligands that are required for HSPC
specification: TGFb1a and TGFb1b in the endothelium, and
TGFb3 from the neighboring notochord. Our data suggest
that TGFb3 is less important for programming of HE but
may instead play a more important role in the EHT process.
In agreement with this, in situ hybridization for HSPC deriva-
tives at 4 dpf showed a more severe phenotype in tgfb3
morphants than in tgfb1 morphants. That TGFb3 has a role
in hematopoiesis was surprising because mouse TGFb3
mutants have no described hematopoietic phenotypes (Gou-
mans and Mummery, 2000). However, TGFb3/ mouse
embryos show loss of palatal fusion due to defective EMT
(Kaartinen et al., 1995; Proetzel et al., 1995). TGFb3 induces
EMT in palate epithelial cells by downregulating E-cadherin
and upregulating fibronectin and vimentin (Nawshad et al.,
2007). This raises the possibility that TGFb may be required
sequentially to generate HSPCs: TGFb1 is required for the
initial HE programming, and then TGFb3 modulates expres-
sion of extracellular matrix components to allow HE cells
to undergo EHT.
Knowledge of how ECs are programmed to become HSCs is
critical to inform attempts to generate these cells in vitro for
therapeutic purposes. Our findings show that TGFb signaling
is required to program the HE that will give rise to HSPCs.
By contrast, we have previously shown that in Xenopus laevis
excessive TGFb signaling blocks specification of the heman-
gioblast population that precedes the formation of HE (Nimmo
et al., 2013). Similarly, adding TGFb2 to Pre-HPCs, a popula-
tion of primitive hematopoietic precursor cells (Ve-Cad+,
CD41+), impairs the EHT process in vitro (Vargel et al., 2016).
This suggests that primitive hematopoiesis is sensitive to
elevated levels of TGFb signaling. Whether excessive TGFb
hinders EHT from the embryonic HE that gives rise to definitive
HSPCs remains to be determined. Our work highlights the
importance of identifying the different spatial and temporal re-
quirements for TGFb signaling in the formation of HSCs and
will help to realize the goal of generating HSCs in vitro for
regenerative medicine.Developmental Cell 38, 358–370, August 22, 2016 367
EXPERIMENTAL PROCEDURES
Ethics Statement
All animal experiments were performed under a Home Office Licence accord-
ing to the Animals Scientific Procedures Act 1986, UK, and approved by the
local ethics committee.
Fish Breeding and Maintenance
Wild-type, Tg(kdrl:GFP)s843 (Jin et al., 2005), Tg(itga2b:GFP)la2 (Lin et al.,
2005), Tg(Kdrl-HsRas-mCherry)s896 (Bertrand et al., 2010), Tg(Fli1-GFP)y1Tg
(Lawson and Weinstein, 2002), and Tg(cmyb:GFP)zf169Tg (North et al., 2007)
fish were bred, maintained, and staged as described (Westerfield, 2000).
Tg(itga2b:gfp; Kdrl-HsRas-mCherry) animals were generated by natural
mating.
Morpholinos and RNA and DNA Injections
Antisense MOs (GeneTools) were used to target runx1 (Gering and Patient,
2005), tgfb3 (tgfb3MO2) (Cheah et al., 2010), kdr + kdrl (Bahary et al., 2007),
and jag1a (Yamamoto et al., 2010) at the amounts specified. TheMOs selected
for this study were tgfbR2MO1, tgfb1aMO2 + tgfb1bMO2 (referred to as tgfb1MO2),
tgfb2MO2, and tgfb3MO2 at the amounts indicated (see Supplemental Experi-
mental Procedures). Typically, 1 nl total volume of MO was injected in 1–4
cell stage embryos. MO design and validation is described in the Supple-
mental Experimental Procedures.
To rescue the loss of HSC markers in tgfbR2 morphants, we transiently ex-
pressed jag1a in ECs under the control of the Kdrl promoter (Jin et al., 2005)
(see Supplemental Experimental Procedures). The amount of DNA used for
the rescue experiment is shown in the figure legends.
Western Blotting
Protein extracts were prepare as described (Link et al., 2006). TgfbR2 protein
was detected by a primary anti-tgfbR2 antibody (diluted 1:250 in blocking so-
lution, sc-17792; Santa Cruz Biotechnology) followed by a goat anti-mouse
horseradish peroxidase (HRP)-conjugated secondary antibody (1:1,000 in
blocking solution, P044701-2, DAKO). An anti b-actin-HRP-conjugated anti-
body (1:35,000, A3854; Sigma) was used for loading control.
NanoString Expression Analysis
To quantitate the effects of tgfbR2 loss of function in and around the embryonic
DA, trunks from anesthetized 26–28 hpf embryos were microdissected with a
straight stab knife. Total RNAwas isolated with the RNEasyMicro kit (QIAGEN)
following the manufacturer’s instructions and quantified in a Nanodrop spec-
trometer. We interrogated expression of a panel of 132 probes (see Supple-
mental Experimental Procedures) using the NanoString nCounter gene
expression system.
mRNA Extraction, Flow Cytometry, cDNA Synthesis, and qPCR
Total RNA was isolated from wild-type or morpholino-injected embryos using
TRI reagent (Sigma) and cleaned using the RNEasy Micro kit (QIAGEN)
following the manufacturer’s instructions. To interrogate gene expression in
ECs of tgfbR2 morphants, uninjected and tgfbR2 MO1-injected Tg(kdrl:gfp)
embryos were dissociated, and kdrl-GFP+ cells were isolated and processed
for mRNA extraction with the RNEasy Micro kit (QIAGEN) as described (Mon-
teiro et al., 2011). cDNA was synthesized from total RNA using a Superscript III
RT-PCR enzyme (Invitrogen) following the manufacturer’s instructions. The
primers used for quantitative real-time PCR (qPCR) are shown in the Supple-
mental Experimental Procedures. Fold changes in gene expression were
calculated using the 2DDCtmethod (Livak and Schmittgen, 2001) and normal-
ized to a geometric mean of bactin2 and ef1a.
In Situ Hybridization, Sections, and Image Acquisition
Whole-mount in situ hybridization was carried out as described (Jowett and
Yan, 1996). cDNA fragments for tgfbR2, tgfb1a, tgfb1b, and tgfb3 were PCR-
amplified from 24 hpf embryo cDNA, cloned into pGEMT-Easy, and used as
templates to generate in situ hybridization probes (see Supplemental Experi-
mental Procedures). After in situ hybridization, embryos were processed and
imaged as described (Gering and Patient, 2005; Monteiro et al., 2011).368 Developmental Cell 38, 358–370, August 22, 2016Fluorescence Imaging and Image Processing
HSPCs express low levels of a GFP transgene under the control of the itga2b
promoter (Kissa et al., 2008). Itga2b:GFPlow, kdrl:HsRas-mCherry+ HSPCs
were imaged in uninjected and morpholino-injected Tg(itga2b:GFP;
Kdrl:HsRas-mCherry) embryos at 48 hpf on a Zeiss LSM780 confocal micro-
scope (Zen software). HSPCs were enumerated in maximum intensity projec-
tion images. GraphPad Prism software was used to generate scatterplots of
cell counts and for statistical analysis. Alternatively, Tg(itga2b:GFP) embryos
were imaged on a Zeiss Lumar V.12 stereomicroscope with an AxioCam
MRm (Zeiss) and AxioVision software.
Apoptosis staining was performed with the Click-IT TUNEL Alexa 594 kit
(C10246; Life Technologies) followed by immunostaining against GFP (see
Supplemental Experimental Procedures).
Images were processed and figures and schemeswere assembled in Adobe
Photoshop CS5 and Adobe Illustrator CS5.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.devcel.2016.06.024.
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